BIO.VI Biogena Group Invest AG
- Market cap
- EUR 19.8M
- P/E
- 70.9x
- P/B
- 2.26x
- ROE
- 3.3%
- Dividend yield
- 1.01%
- Fundamental score
- 1.8/5
Ratios use the latest price and the fiscal year ending Jan 2026.
Is BIO.VI undervalued?
Graham numberBIO.VI trades 166.7% above its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
Biogena Group Invest AG fundamental analysis
8 of 22 checks passedROE 0/2
Low return on equity (3.3%), below 10%.
ROA 1/1
Return on assets (3.3%) is above the industry median (2.7%).
Profit Consistency 2/2
Profitable for 6 consecutive years.
Earnings Growth 5Y 1/1
Earnings per share grew over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-11.2%) is not above the 5-year average (4.7% a year).
Earnings Growth vs Industry 1/1
Last year's EPS growth (-11.2%) is above the industry median (-17.0%).
Revenue Growth 2/2
Revenue grew 11.8% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
EBIT is 29,685,503.0x against interest expense, well covered.
PE vs Market 0/1
PE (70.9x) is above the market median (18.5x).
PE vs Industry 0/1
PE (70.9x) is above the industry median (10.5x).
PBV 0/1
Price to book (2.3x) is above the industry median (1.1x).
Graham Number 0/1
The price is above the Graham number (PE x PB = 160.0, limit 22.5).
PEG 0/1
PEG on 5-year earnings growth is 15.12, above 1.
Dividend Yield 0/2
No dividend paid in the last reported year.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 0/1
No dividend, or no profit to pay it from.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
Biogena Group Invest AG stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About Biogena Group Invest AG
Biogena Group Invest AG engages in the provision of dietary supplements. The company is based in Salzburg, Austria.
Full company profileBiogena Group Invest AG financial statements
Biogena Group Invest AG annual financial statements (EUR; K = thousand, M = million, B = billion, T = trillion)
| Item | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
|---|---|---|---|---|---|---|
| Income Statement | ||||||
| Revenue | 329K | 331K | 251K | 166K | 368K | 351K |
| Gross Profit | 329K | 330K | 250K | 165K | 368K | 351K |
| Operating Income | 39.9K | -75.8K | 93.2K | 3.43K | 196K | 179K |
| EBITDA | 151K | 817K | 302K | 176K | 334K | 297K |
| Net Income | 117K | 735K | 298K | 172K | 330K | 293K |
| EPS | 0.06 | 0.18 | 0.07 | 0.04 | 0.08 | 0.07 |
| Balance Sheet | ||||||
| Total Assets | 2.29M | 8.75M | 8.70M | 8.86M | 8.94M | 8.86M |
| Total Liabilities | 108K | 128K | 179K | 366K | 238K | 62.9K |
| Shareholders' Equity | 2.18M | 8.62M | 8.52M | 8.49M | 8.70M | 8.80M |
| Cash & Short-term Investments | 206K | 17.4K | 24.5K | 23.0K | 12.3K | 23.6K |
| Total Debt | 242.50 | - | - | - | - | - |
| Cash Flow | ||||||
| Operating Cash Flow | - | - | - | 25.0K | -9.00K | - |
| Capital Expenditure | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Free Cash Flow | - | - | - | 25.0K | -9.00K | - |
| Ratios | ||||||
| ROE | 5.4% | 8.5% | 3.5% | 2.0% | 3.8% | 3.3% |
| ROA | 5.1% | 8.4% | 3.4% | 1.9% | 3.7% | 3.3% |
| Net Profit Margin | 35.4% | 222.1% | 118.8% | 103.8% | 89.7% | 83.6% |
| Debt to Equity | 0.00x | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
Biogena Group Invest AG dividends
- Dividend yield
- 1.01%
- Forward dividend
- 0.05 EUR
- Payout ratio
- -
- Ex-dividend date
- Apr 15, 2026
Who owns Biogena Group Invest AG
Ownership data of Biogena Group Invest AG is not available yet.
Biogena Group Invest AG company profile
- Company name
- Biogena Group Invest AG
- Ticker
- BIO.VI
- ISIN
- ATBIOGENA005
- Exchange
- Vienna Exchange
- Sector
- Consumer Defensive
- Industry
- Packaged Foods
- Fiscal year end
- January
- Address
- Strubergasse 24, Salzburg, Austria, 5020
- Website
- biogenagroup.com
About Biogena Group Invest AG
Biogena Group Invest AG engages in the provision of dietary supplements. The company is based in Salzburg, Austria.
Biogena Group Invest AG management
2- Ms. Julia Hoffmann M.Sc.Member of the Management Board · born 1989
- Mr. Stefan KlinglmairMember of the Management Board · born 1978